Ibrutinib in previously treated patients with Waldenström's macroglobulinemia is highly active, produces durable responses, and is impacted by MYD88 and CXCR4 mutation status Meeting Abstract

   

Authors:	Treon, S.; Tripsas, C.; Meid, K.; Warren, D.; Varma, G.; Green, R.; Argyropoulos, K.; Yang, G.; Cao, Y.; Xu, L.; Patterson, C.; Rodig, S.; Zehnder, J.; Aster, J.; Harris, N. L.; Kanan, S.; Ghobrial, I.; Laubach, J.; Hunter, Z.; Salman, Z.; Cheng, M.; Li, J.; Clow, F.; Graef, T.; Castillo, J.; Palomba, M. L.; Advani, R.
Abstract Title:	Ibrutinib in previously treated patients with Waldenström's macroglobulinemia is highly active, produces durable responses, and is impacted by MYD88 and CXCR4 mutation status
Meeting Title:	20th Congress of the European Hematology Association (EHA)
Journal Title:	Haematologica
Volume:	100
Issue:	Suppl. 1
Meeting Dates:	2015 Jun 11-14
Meeting Location:	Vienna, Austria
ISSN:	0390-6078
Publisher:	Ferrata Storti Foundation
Date Published:	2015-06-01
Start Page:	311
Language:	English
ACCESSION:	WOS:000361204902289
PROVIDER:	wos
PMCID:	PMC4480587
Notes:	Meeting Abstract: S785 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/82757